Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.

UNLABELLED Dopamine D2 receptor function was assessed in a PET study with 2 dopamine D2 receptor PET ligands, [11C]raclopride (RAC) and [11C]N-methylspiperone (NMSP), in early Parkinson's disease. METHODS Seven patients with early Parkinson's disease and 5 healthy volunteers were studied. Each underwent PET both with reversible [11C]RAC and with irreversible [11C]NMSP. RESULTS Upregulation of dopamine D2 receptors in the putamen contralateral to the predominant symptoms of Parkinson's disease was confirmed using both [11C]RAC and [11C]NMSP. Uptake of [11C]RAC in the contralateral putamen was 105% of uptake in the opposite putamen (P = 0.020). For [11C]NMSP, uptake in the contralateral putamen was 105% of uptake in the ipsilateral putamen (P = 0.011). No significant differences between Parkinson's disease patients and healthy volunteers were detected in any of the studied brain regions using either [11C]RAC or [11C]NMSP. No significant differences between [11C]RAC and [11C]NMSP uptake were detected in the striatum, whereas in the extrastriatal regions, [11C]NMSP showed significantly higher uptake than [11C]RAC both in healthy volunteers and in Parkinson's disease patients. CONCLUSION This study confirms an increase in dopamine D2 receptors in the putamen contralateral to the predominant symptoms, compared with the ipsilateral putamen, in early Parkinson's disease. This increase was seen both with reversible ligand [11C]RAC and with irreversible ligand [11C]NMSP and thus does not seem a consequence of depleted endogenous dopamine.

[1]  J. Rinne,et al.  Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[2]  Ulla Ruotsalainen,et al.  Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride , 1995, Journal of the Neurological Sciences.

[3]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[4]  K. L. Leenders,et al.  Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers , 1988, Brain Research.

[5]  C. Pelizzari,et al.  Accurate Three‐Dimensional Registration of CT, PET, and/or MR Images of the Brain , 1989, Journal of computer assisted tomography.

[6]  G. Antoni,et al.  The synthesis of 1-11C-labelled ethyl, propyl, butyl and isobutyl iodides and examples of alkylation reactions , 1986 .

[7]  D. Wong,et al.  Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain , 1991, Synapse.

[8]  P. Hartvig,et al.  Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C‐N‐methyl‐spiperone , 1987, Acta neurologica Scandinavica.

[9]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[10]  J S Fowler,et al.  Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.

[11]  A. Antonini,et al.  [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.

[12]  K. Någren,et al.  Improved synthesis of some commonly used PET radioligands by the use of [11C]methyl triflate. , 1995, Nuclear medicine and biology.

[13]  S. Snyder,et al.  Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. , 1977, Science.

[14]  U Ruotsalainen,et al.  PET study on striatal dopamine D2 receptor changes during the progression of early parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[15]  J M Links,et al.  3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[16]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[17]  C. Halldin,et al.  A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[18]  C. Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  U Ruotsalainen,et al.  Decrease in Human Striatal Dopamine D2 Receptor Density with Age: A PET Study with [11C]Raclopride , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  K. Leenders,et al.  Comparison of 123I‐IBZM SPECT and 11C‐raclopride PET findings in patients with parkinsonism , 1994, Nuclear medicine communications.

[21]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  K. Någren,et al.  PET demonstrates different behaviour of striatal dopamine D‐1 and D‐2 receptors in early Parkinson's disease , 1990, Journal of neuroscience research.

[23]  O. Hornykiewicz,et al.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.

[24]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[25]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[26]  P. Seeman,et al.  Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.

[27]  Michael J. Adam,et al.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.

[28]  M. Raichle,et al.  MPTP‐induced up‐regulation of in vivo dopaminergic radioligand‐receptor binding in humans , 1987, Neurology.

[29]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  C. Halldin,et al.  Comparison of the In Vitro Receptor Binding Properties of N‐[3H]Methylspiperone and [3H]Raclopride to Rat and Human Brain Membranes , 1990, Journal of neurochemistry.

[31]  R S Frackowiak,et al.  Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.